GmbH, Reinbek, Germany) and MI was tested, from May 2012, at 500 ppm in water (0.05%) (TROLAB ® patch test allergens). Allergens were applied for 48 hr on the back, with Finn Chambers ® on Scanpor ® tape (Epitest Ltd, Vellinge, Sweden), or IQ Ultra Chambers™ (Chemotechnique, Vellinge, Sweden). The readings were performed on D2 or D3 and D4 or D7.
We observed a significant increase in isothiazolinone sensitization. The prevalence rose from < 1% in 2005 to 3.24% in 2008. After 2012, and with the addition of the MI patch test, the sensitization rates increased to 5.15% in 2012, and doubled to 10.9% in the first half of 2013 ( Fig. 1) .
After 2011, we observed a total of 35 patients with positive reactions to isothiazolinones, 20% men (n = 7) and 80% women (n = 28), ranging in age from 3 to 72 years. The percentage of patients with an isothiazolinone-positive patch test reaction in the different semesters is shown in Fig. 2 . Definitive relevance was established in 33 (94.3%) patients, mostly to cosmetics and occupational activities. Eighteen cases (51.4%) were related to professional activity (6 nurses, 3 hairdressers, a beautician, 5 cleaners or workers who also clean their workplaces, and 2 factory workers). 15/35 (42.9%) patients had a positive patch test reaction to a personal product containing isothiazolinones. To better evaluate the clinical implications of IS sensitization, we contacted by telephone 11 of 20 patients in whom a causal relationship with products that were contacted daily was not positively traced, and 10 reported clinical improvement after avoiding isothiazolinone-containing products. Moreover, 2 hairdressers changed their job because of clinically severe symptomatology.
Discussion
The rate of isothiazolinone sensitization in our population has been increasing consistently since 2005; this increase was more pronounced in 2012, when the MI patch test was introduced. Moreover, we observed 8 of 28 cases reacting exclusively to MI; therefore, this patch test was essential for the diagnosis of isothiazolinone sensitization in 28.6% of patients.
The permitted concentration of MI in Europe should be urgently revised. In an MI-sensitized population, 64% reacted to products containing 50 ppm, whereas only 18% reacted to products containing 5 ppm (2). Definite clarification of the primary sensitizer requires testing with MCI and MI separately (3, 4, 5) . However, in our study, the asymmetrical patterns of reactivity to MI and MCI/MI, and the higher intensity of the reactions (usually greater intensity for MI than for MCI/MI), support primary sensitization to MI in numerous cases.
